1.Pharmacological effects: Imiquimod can enhance cellular immune activity, in the drug local induction of inflammatory response and the production of a variety of cytokines, through the immune regulation to play an indirect antiviral effect. Imiquimod is effective in inducing a variety of cytokines including α-, interferon (, IFN, -α) and α-, tumor necrosis factor (, TNF, -α) both in vivo and in vitro. In cellular experiments, imiquimod induced human peripheral monocytes to produce cytokines such as IFN, -α, TNF, -, α, IL, -, 1α, IL, -, 1β, IL, -6, 8, IL, -, 10,, GM, -, CSF, MCP, -, 1α (monocyte chemotactic protein-1α),, MCP, -, 1β, etc.,. The concentrations of IFN,-α and TNF,-α in the local skin peaked after topical application of imiquimod cream (0.,05 μg/, cm2,), 1h. The 2 metabolites of imiquimod, S,-26704 and S,-22770, have similar immunologic activity.HPV can enter the body through tiny abrasions on the skin surface, and warts are formed after a period of incubation (usually 3-8 weeks).A small amount of imiquimod can penetrate into the superficial layers of the skin, inducing the production of interferon. Through interferon, an active antiviral factor, it restricts the proliferation of HPV virus and inhibits the proliferation of HPV-infected keratinocytes. The cytokines induced by imiquimod induce monocyte nuclei and other leukocytes to converge towards the wart tissue, and the activated dendritic cells process the HPV antigens and present them to the lymph nodes, where they activate HPV-specific T-lymphocytes and release them into the bloodstream.After entering the wart, the HPV-specific T-lymphocytes kill the HPV-infected cells, and monocytes and macrophages further phagocytose the cellular debris. Through the establishment of HPV-specific T-lymphocyte immune memory, to achieve rapid treatment of any type of HPV infection, and then significantly reduce the recurrence rate of acromegaly. 2, in vivo and ex vivo experiments: imiquimod cream maximum concentration of 18., 3%, according to 110g/kg administration, local administration of toxicity test in white rabbits, continuous administration of 1 week, in addition to the formation of a slight erythema, did not see obvious skin irritation, did not find sensitizing effect on the skin of guinea pigs. In addition, animal tests have demonstrated that imiquimod is not carcinogenic, mutagenic or teratogenic. Skin tolerance test showed that imiquimod is not irritating to normal human skin. Using radiolabeling techniques in 7 patients who used imiquimod, it was found to be minimally absorbed, and the drug was not detected in the serum after application, and only 2% was measured in urine and feces. Pharmacokinetics: 6 healthy subjects were given a single topical dose of 5 mg, 14C-labeled imiquimod cream, and the study showed that, 14C-labeled imiquimod had minimal percutaneous reabsorption. With topical imiquimod, no radioactivity was detected in serum (lowest limit of detection: 1 μg/mL), and the amount of radioactivity in urine and feces was less than 0.9% of the labeled amount. 4, adverse reactions: 5% imiquimod cream in the treatment of no systemic adverse reactions, no interferon fever, flu-like symptoms and other systemic adverse reactions, will not damage the skin tissue. However, in the mucous membrane and semi-mucous membrane areas, the tissues are tender, thus there are some mild and moderate irritation. The most common are erythema in about 61%, vesicles in about 30%, desquamation in about 23%, and edema in about 14%. Local irritation inflammatory reaction often occurs in the 2nd, ~ 5 weeks, mostly mild, moderate, short duration, about 4 ~ 12d, usually stopping the drug 7 ~ 12d after the disappearance of the irritation reaction. Some subjective symptoms can also occur, such as itching, about 22%, burning about 13%, pain and tenderness about 5%.